News & Trends - Pharmaceuticals
Novartis challenges hospitals over copycat cancer treatment, fuelling debate on access

Pharma News: Novartis ANZ is urging Australian hospitals to halt the production of copycat alternatives to its innovative radioligand therapy, Pluvicto.
The current intellectual property framework fails to acknowledge the substantial financial investments of billions of dollars made by pharmaceutical companies in developing innovative treatments. It acts as a disincentive for ongoing research and investment in Australia.
Doctors at St Vincent’s Hospital in Sydney, including the Director of Nuclear Medicine, Louise Emmett, defend their compounded treatments, which cost $6,000 per dose compared to $80,000 for two doses of Pluvicto. They assert that their alternatives are both safe and effective. This disagreement has sparked a wider debate on the accessibility of life-extending cancer treatments, with Novartis allegedly threatening potential legal action.
The Australasian Association of Nuclear Medicine Specialists (AANMS) has applied to the Medical Services Advisory Committee (MSAC) for public funding of these treatments to ensure availability for all patients in need. In April, MSAC recommended that the treatment be covered by Medicare, but the final decision now lies with the federal government.
However, Novartis has cautioned MSAC that there is insufficient evidence to establish therapeutic equivalence between 177LuPSMA i&t and Pluvicto, stating that the existing data does not permit a reliable clinical comparison between these two structurally different products.
Novartis ANZ joined forces with Queensland Health and the University of Queensland to launch the “Bench to Bedside” report and host a roundtable discussion on the impact of these cutting-edge therapies on patients in Queensland and the wider radiopharmaceutical industry. Policymakers, industry leaders, academic experts, and patient advocates from the Prostate Cancer Foundation of Australia (PCFA) gathered to discuss the potential of radioligand therapies and strategies for improving cancer care.
A recently released discussion paper, developed by MTPConnect and supported by Novartis and other partners, also highlighted the nation’s readiness to lead the growing global radiopharmaceutical industry, with advanced therapies driving significant investment and expansion.
Novartis has made radiopharmaceuticals a key part of its oncology portfolio, marked by the recent Therapeutic Goods Administration (TGA) approval of Pluvicto. Despite this milestone, access remains a challenge due to the lack of government funding for wider and more equitable patient access.
Pluvicto has been hailed as a breakthrough for late-stage prostate cancer, and now shows potential for improving outcomes in earlier stages of the disease. A new study led by Peter MacCallum Cancer Centre, presented at the European Society for Medical Oncology (ESMO) Congress 2024, unveiled “remarkable” trial results, offering new hope for patients.
St Vincent’s Hospital clinicians are emphasising the urgent need for affordable treatment options, particularly for older patients with advanced prostate cancer, many of whom are already facing significant financial and health challenges.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo
The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]
MoreNews & Trends - Pharmaceuticals

AI-powered test to reshape use of hormone therapy in prostate cancer
Australian researchers are pioneering the use of artificial intelligence (AI) to enhance decision-making in prostate cancer treatment, specifically focusing on […]
MoreNews & Trends - MedTech & Diagnostics

Vantive debuts as standalone business amid complex landscape of chronic kidney disease
Vantive, formerly Baxter’s Kidney Care business, has officially launched as a standalone company. The move follows Baxter’s completion of the […]
MoreNews & Trends - MedTech & Diagnostics

Optalert unveils test for sleep apnoea as Philips expands partnership in pharmacy program
An Australian medical technology company has introduced a test designed to identify obstructive sleep apnoea (OSA), broadening access to sleep […]
More